How Novo Revitalized Its Rare Disease Operations
Executive Summary
There is more to the Danish major than diabetes and Ludovic Helfgott gave In Vivo an insight to the firm’s ambitious plans for its renamed rare diseases division.
You may also be interested in...
Novo Nordisk’s Forma Buy Builds On Foothold In Rare Blood Disorders
Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.
Novo’s Sogroya Impresses In Children With Convenience Advantage Over SOC
The Danish firm’s injectable growth hormone analogue has succeeded in a late-stage study of children with a growth disorder and offers more convenient dosing that could improve adherence.
RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.